Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab
- DOI
- 10.1038/sj.bjc.6605972
- Published
- 2010-11-23
- Container
- British Journal of Cancer
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
serious concern Score 29/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- serious concernRetraction Watch retraction: 1 retraction notice matched this DOI.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1038/sj.bjc.6605972,
title = {Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab},
author = {A Gualberto and M L Hixon and D D Karp and D Li and S Green and M Dolled-Filhart and L G Paz-Ares and S Novello and J Blakely and C J Langer and M N Pollak},
year = {2010},
journal = {British Journal of Cancer},
doi = {10.1038/sj.bjc.6605972},
url = {https://doi.org/10.1038/sj.bjc.6605972}
}RIS
TY - JOUR TI - Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab AU - A Gualberto AU - M L Hixon AU - D D Karp AU - D Li AU - S Green AU - M Dolled-Filhart AU - L G Paz-Ares AU - S Novello AU - J Blakely AU - C J Langer AU - M N Pollak PY - 2010 JO - British Journal of Cancer DO - 10.1038/sj.bjc.6605972 UR - https://doi.org/10.1038/sj.bjc.6605972 ER -
APA
Gualberto, A., Hixon, M. L., Karp, D. D., Li, D., Green, S., Dolled-Filhart, M., Paz-Ares, L. G., Novello, S., Blakely, J., Langer, C. J., & Pollak, M. N. (2010). Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6605972
Source records
- crossref · retrieved 2026-11-10T10:05:10.601Z